(Q42639421)

4 November 2017

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study (English)

1 reference

4 November 2017

1 reference

K H Yoon

1

1 reference

4 November 2017

H Steinberg

2

1 reference

4 November 2017

R Teng

3

1 reference

4 November 2017

G T Golm

4

1 reference

4 November 2017

M Lee

5

1 reference

4 November 2017

E A O'Neill

6

1 reference

4 November 2017

K D Kaufman

7

1 reference

4 November 2017

B J Goldstein

8

1 reference

4 November 2017

17 April 2012

1 reference

Diabetes, Obesity and Metabolism

4 November 2017

1 reference

4 November 2017

14

1 reference

4 November 2017

8

1 reference

4 November 2017

745-752

1 reference

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

4 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Type 2 diabetes--treat early, treat intensively

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Insulin-dependent actions of pioglitazone in newly diagnosed, drug naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01594.X

10.1111/J.1463-1326.2012.01594.X

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference